Discovery, optimization, and phase 1 evaluation of a novel, orally available GLP-1R/GIPR dual agonist

化学 相(物质) 对偶(语法数字) 药理学 医学 材料科学 计算机科学 生物医学工程 药代动力学 生物系统
作者
Stephanie A. Mowery,Patrick J. Knerr,Karina Rahr Hjøllund,Birgitte Nissen,Anette K. Olsen,Trine Levring Wilkens,Lasse Hjort Jakobsen,Christian Hollesen,Kateryna Breusova,Joyce E. Sorrell,Diego Pérez–Tilve,Brian Finan,Richard D. DiMarchi,Charlotta Dornonville de la Cour
出处
期刊:Molecular metabolism [Elsevier BV]
卷期号:115: 102470-102470
标识
DOI:10.1016/j.molmet.2026.102470
摘要

OBJECTIVES: The efficacy and convenience of anti-diabetic and anti-obesity therapeutics have surged in recent years due to the emergence of incretin-based poly-pharmacological approaches as well as advances in the oral delivery of peptide drugs. We sought to combine both strategies in an orally deliverable dual agonist of the GLP-1 and GIP receptors. METHODOLOGY: We designed a panel of unimolecular, fatty-acylated peptide dual agonists, which was screened for receptor potencies in cell-based assay systems. NNC0130 was selected to advance into clinical studies using both oral and subcutaneous administration. RESULTS: NNC0130 exhibited in vitro potency comparable to semaglutide at human GLP-1R and to tirzepatide at human GIPR, with a chemical structure compatible with semi-recombinant production. Its human half-life of 76-89 h was deemed suitable for once-daily oral administration. In a multiple-ascending dose trial in participants with overweight or obesity and with separate subcutaneous and oral cohorts, daily subcutaneous administration of NNC0130 escalating from 0.3 to 3.0 mg per dose provided a placebo-corrected mean body weight loss of 9% after 12 weeks of treatment and 12% after 15 weeks. Daily oral administration escalating from 5 to 50 mg per dose provided a placebo-corrected mean body weight loss of 4% after 12 weeks, which was not statistically significantly different from zero. The relative oral bioavailability when co-formulated with permeation enhancer sodium N-(8-[2-hydroxybenzoyl]amino)caprylate was estimated to 1.6-2.2% versus s. c. administration. CONCLUSIONS: The modest weight-lowering efficacy of orally administered NNC0130 highlights the continued challenges of low oral bioavailability of acylated peptides. However, the substantial efficacy observed with subcutaneous administration motivated advancement into Phase 2 clinical development.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
李瑞程发布了新的文献求助10
2秒前
Lotus发布了新的文献求助10
2秒前
2秒前
都瓦克因完成签到,获得积分10
3秒前
fengjingjing发布了新的文献求助10
3秒前
今后的应助被ZRT采纳,获得10
3秒前
小马甲的应助被栗子采纳,获得10
3秒前
纯真笑白完成签到 ,获得积分10
3秒前
5秒前
6秒前
Lily发布了新的文献求助10
6秒前
7秒前
嗷嗷ao发布了新的文献求助10
7秒前
无极微光的应助被小月月采纳,获得20
7秒前
Guozixin完成签到 ,获得积分10
8秒前
8秒前
樱满集完成签到,获得积分20
8秒前
顺利追命完成签到 ,获得积分10
9秒前
Citrofrost完成签到,获得积分10
9秒前
10秒前
领导范儿的应助被袋袋采纳,获得10
10秒前
叫滚滚发布了新的文献求助10
11秒前
12秒前
12秒前
yebo发布了新的文献求助10
12秒前
lmy发布了新的文献求助10
12秒前
12秒前
13秒前
whatever的应助被女巫在跳舞采纳,获得50
14秒前
15秒前
小亮完成签到 ,获得积分10
16秒前
lingo发布了新的文献求助20
17秒前
chen完成签到,获得积分20
18秒前
胡佳琦发布了新的文献求助10
18秒前
科研通AI6.4的应助被孙家贝采纳,获得10
18秒前
19秒前
1461644768完成签到,获得积分10
19秒前
风吹麦浪发布了新的文献求助10
19秒前
在水一方的应助被zzk采纳,获得10
19秒前
领导范儿的应助被loren采纳,获得20
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183263
求助须知:如何正确求助?哪些是违规求助? 9572532
关于积分的说明 21826339
捐赠科研通 7780187
什么是DOI,文献DOI怎么找? 3433993
关于科研通互助平台的介绍 2558131
邀请新用户注册赠送积分活动 2480239